b
r
c
background
coronaviru
one
caus
common
cold
exacerb
chronic
obstruct
pulmonari
diseas
copd
bronchial
asthma
longact
muscarin
antagonist
b
agonist
inhal
corticosteroid
inhibit
exacerb
copd
bronchial
asthma
caus
infect
virus
includ
pleas
cite
articl
yamaya
et
al
inhibitori
effect
glycopyrronium
formoterol
budesonid
coronaviru
replic
cytokin
product
primari
cultur
human
nasal
tracheal
epitheli
cell
respiratori
investig
http
avail
onlin
xxx
keyword
airway
epitheli
cell
longact
b
agonist
longact
muscarin
antagonist
howev
effect
drug
replic
infectioninduc
inflamm
human
airway
unknown
method
primari
human
nasal
hne
tracheal
hte
epitheli
cell
cultur
infect
result
pretreat
hne
hte
cell
glycopyrronium
formoterol
decreas
viral
rna
level
andor
titer
express
receptor
number
fluoresc
intens
acid
endosom
rna
enter
cytoplasm
infectioninduc
product
cytokin
includ
ifnb
treatment
cell
inhibitor
dipyridyl
decreas
viral
titer
pretreat
cell
combin
three
drug
glycopyrronium
formoterol
budesonid
exert
addit
inhibitori
effect
viral
titer
cytokin
product
pretreat
hne
cell
glycopyrronium
formoterol
reduc
suscept
infect
pretreat
three
drug
inhibit
activ
nuclear
factorkappa
b
protein
pretreat
formoterol
increas
camp
level
treatment
camp
decreas
viral
titer
express
fluoresc
intens
acid
endosom
conclus
find
suggest
glycopyrronium
formoterol
combin
glycopyrronium
formoterol
budesonid
inhibit
replic
partli
inhibit
receptor
express
andor
endosom
function
drug
modul
infectioninduc
inflamm
airway
inhibitori
effect
glycopyrronium
formoterol
budesonid
coronaviru
replic
cytokin
product
primari
cultur
human
nasal
tracheal
epitheli
cell
human
coronavirus
hcov
caus
common
cold
exacerb
chronic
obstruct
pulmonari
diseas
copd
bronchial
asthma
bind
aminopeptidas
n
receptor
enter
cell
via
endosom
cellsurfac
pathway
use
proteas
replic
airway
epitheli
cell
line
howev
replic
primari
human
airway
epitheli
cell
cultur
studi
longact
muscarin
antagonist
lama
longact
b
agonist
laba
inhal
corticosteroid
icss
prevent
copd
bronchial
asthma
exacerb
induc
viral
infect
includ
infect
report
lama
tiotropium
laba
formoterol
ic
budesonid
reduc
rhinoviru
replic
reduc
receptor
express
andor
number
acid
endosom
rhinovir
rna
enter
cytoplasm
acid
endosom
also
critic
entri
howev
effect
drug
replic
unknown
clinic
benefit
drug
may
relat
variou
effect
includ
inhibit
viral
infectioninduc
cytokin
product
bronchospasm
mucu
hypersecret
howev
effect
drug
infectioninduc
cytokin
product
airway
cell
unclear
present
studi
examin
inhibitori
effect
lama
glycopyrronium
laba
formoterol
ic
budesonid
replic
primari
human
nasal
epitheli
hne
human
tracheal
epitheli
hte
cell
cultur
filter
membran
airinterfac
method
exhibit
higher
differenti
cultur
immers
condit
also
examin
effect
drug
express
acid
endosom
studi
mechan
underli
effect
materi
method
nasal
polyp
obtain
subject
chronic
rhinosinus
age
undergo
endoscop
surgeri
tracheal
sampl
obtain
patient
death
age
year
sex
reason
surgeri
caus
death
presenc
allerg
rhiniti
bronchial
asthma
copd
well
drug
use
treatment
shown
tabl
total
subject
treat
nasal
corticosteroid
oral
corticosteroid
icss
laba
lama
respect
one
tracheal
sampl
donor
copd
studi
approv
tohoku
univers
ethic
committe
irb
number
cell
cultur
filter
membran
transwel
corn
usa
plate
becton
dickinson
nj
usa
coverslip
petridish
stock
clinic
isol
prepar
infect
rhesu
monkey
kidney
epitheli
cell
airway
surfac
liquid
asl
detect
titrat
use
cell
endpoint
method
nd
nt
cr
nd
ns
f
cr
ba
os
ic
laba
f
cr
nd
nt
cr
nd
nt
cr
ba
ns
cr
nd
nt
cr
ba
ns
ic
laba
cr
nd
ns
f
cr
ar
os
cr
nd
nt
cr
nd
ns
f
cr
ba
os
ic
laba
cr
nd
nt
cr
ba
ns
ic
laba
cr
ba
ic
laba
cr
nd
ns
cr
ba
ar
ic
laba
cr
nd
ns
f
cr
ba
ar
ns
cr
nd
nt
cr
nd
nt
f
cr
ba
ar
ic
laba
cr
nd
nt
cr
nd
ns
f
cr
ba
ic
laba
cr
nd
ns
cr
nd
nt
cr
ar
hne
hte
cell
infect
multipl
infect
min
accord
method
describ
previou
report
use
rhinoviru
subsequ
cultur
c
collect
airway
surfac
liquid
basolater
supernat
analysi
asl
collect
rins
apic
surfac
hne
hte
cell
ml
fresh
medium
infect
h
h
h
h
infect
collect
medium
use
examin
titer
level
cyclic
amp
camp
interleukin
il
interferon
ifn
basolater
supernat
collect
replac
fresh
medium
use
measur
camp
ifn
level
cell
pretreat
drug
nm
start
h
infect
last
end
experiment
period
determin
concentrationdepend
effect
drug
cell
pretreat
drug
concentr
rang
uninfect
cell
pretreat
drug
nm
h
examin
effect
express
acid
endosom
nuclear
factorkappa
b
nfkb
activ
drug
obtain
astrazeneca
plc
cambridg
uk
effect
drug
suscept
infect
cell
pretreat
drug
nm
h
infect
suscept
infect
evalu
previous
describ
quantif
rna
mrna
level
interferon
level
rna
mrna
ifnb
ifnl
ifng
determin
use
realtim
quantit
revers
transcript
rt
pcr
use
gene
express
master
mix
appli
biosystem
ca
usa
tb
green
premix
ex
takara
shiga
japan
previous
describ
measur
camp
cytokin
product
nfkb
activ
level
camp
measur
use
enzymelink
immunosorb
assay
elisa
kit
boster
bio
ca
usa
cyclic
amp
select
enzym
immunoassay
eia
kit
cayman
chemic
mi
usa
solid
phase
chemiluminesc
elisa
kit
elisa
r
system
mn
usa
eia
kit
invitrogen
ca
usa
level
ifnb
ifnl
ifng
measur
use
human
ifnb
quantikin
elisa
kit
human
ifnl
duoset
elisa
kit
r
system
quantikin
human
ifng
immunoassay
kit
presenc
transloc
nuclear
extract
assess
use
transam
nfkb
famili
kit
activ
motif
previous
describ
distribut
fluoresc
intens
acid
endosom
cell
measur
lysosensor
dye
molecular
probe
usa
use
livecel
imag
fluoresc
intens
calcul
use
fluoresc
imag
analyz
system
lumina
mitani
fukui
japan
result
express
mean
standard
error
mean
sem
statist
analysi
perform
use
twoway
repeat
measur
analysi
varianc
anova
subsequ
posthoc
analys
perform
use
bonferroni
method
student
ttest
use
comparison
two
group
valu
p
indic
signific
differ
experi
n
refer
number
donor
nasal
tissu
trachea
epitheli
cell
obtain
analys
perform
use
spss
version
ibm
japan
tokyo
japan
detect
asl
h
infect
increas
h
h
p
anova
peak
titer
observ
h
h
fig
pretreat
glycopyrronium
nm
formoterol
nm
combin
glycopyrronium
formoterol
budesonid
gfb
nm
drug
decreas
viral
titer
fig
howev
treatment
budesonid
alon
nm
decreas
viral
titer
fig
e
viral
titer
gfbpretreat
cell
lower
cell
treat
glycopyrronium
formoterol
budesonid
alon
fig
select
b
adrenerg
receptor
antagonist
ici
ici
sigmaaldrich
mo
usa
revers
inhibitori
effect
formoterol
viral
titer
inhibitor
reduc
viral
titer
fig
peak
titer
cell
asthmat
patient
log
tcid
ml
n
tcid
tissu
cultur
infect
dose
defin
accord
global
initi
asthma
guidelin
titer
allerg
rhiniti
patient
log
tcid
ml
n
tend
higher
patient
without
asthma
allerg
rhiniti
log
tcid
ml
n
howev
differ
signific
p
pretreat
glycopyrronium
formoterol
gfb
decreas
rna
level
h
infect
ici
revers
effect
formoterol
fig
rna
level
gfbpretreat
cell
lower
cell
treat
glycopyrronium
formoterol
budesonid
alon
fig
result
present
mean
sem
five
ad
feh
seven
e
subject
signific
differ
compar
cell
pretreat
vehicl
indic
p
p
p
signific
differ
compar
cell
treat
glycopyrronium
formoterol
budesonid
indic
p
p
p
respect
viral
releas
measur
asl
collect
h
infect
minimum
dose
necessari
infect
hne
cell
pretreat
glycopyrronium
formoterol
gfb
higher
dose
need
infect
vehicletr
cell
ici
revers
effect
formoterol
fig
concentrationdepend
effect
replic
pretreat
hne
cell
glycopyrronium
concentr
nm
higher
formoterol
nm
higher
gfb
nm
higher
reduc
titer
concentrationdepend
manner
fig
pretreat
budesonid
concentr
less
mm
reduc
e
titer
uninfect
hne
cell
express
signific
amount
mrna
protein
detect
asl
fig
b
mrna
protein
level
cell
treat
formoterol
gfb
lower
vehicletr
cell
fig
b
treatment
glycopyrronium
budesonid
alon
affect
express
treatment
hne
cell
glycopyrronium
formoterol
gfb
reduc
number
fluoresc
intens
acid
endosom
fig
ici
revers
effect
formoterol
fig
effect
formoterol
camp
product
effect
camp
viral
replic
camp
level
basolater
supernat
increas
approxim
mm
h
treatment
formoterol
fig
furthermor
pretreat
camp
mm
mm
reduc
viral
titer
mrna
protein
level
well
fluoresc
intens
acid
endosom
fig
level
asl
uninfect
hne
cell
cultur
h
h
differ
time
fig
b
infect
increas
level
cell
cultur
h
level
cell
cultur
h
fig
b
nfkb
inhibitor
caffeic
acid
phenethyl
ester
cape
mgml
calbiochem
ca
usa
reduc
level
infect
fig
b
infect
pretreat
formoterol
budesonid
gfb
glycopyrronium
reduc
baselin
aeg
concentr
glycopyrronium
formoterol
budesonid
nm
result
present
mean
sem
five
b
eight
g
subject
signific
differ
compar
cell
pretreat
vehicl
indic
p
p
b
g
signific
differ
compar
cell
pretreat
formoterol
indic
p
yy
p
b
g
signific
differ
compar
cell
pretreat
glycopyrronium
indic
p
b
secret
compar
vehicletr
cell
fig
pretreat
glycopyrronium
formoterol
budesonid
gfb
reduc
infectioninduc
secret
compar
vehicletr
cell
fig
concentr
gfbtreat
cell
lower
cell
treat
glycopyrronium
formoterol
budesonid
alon
fig
mrna
level
ifnb
ifnl
ifng
hne
cell
increas
infect
pretreat
glycopyrronium
formoterol
budesonid
gfb
decreas
level
fig
contrast
concentr
ifnb
ifnl
ifng
asl
basolater
supernat
detect
limit
pgml
ifnb
pgml
ifnl
pgml
ifng
infect
effect
nfkb
glycopyrronium
formoterol
budesonid
treatment
uninfect
hne
cell
reduc
amount
nfkb
nuclear
extract
compar
vehicletr
cell
effect
gfb
addit
fig
also
confirm
effect
drug
replic
hte
cell
pretreat
glycopyrronium
nm
formoterol
nm
gfb
nm
mm
decreas
titer
moreov
viral
titer
gfbtreat
cell
lower
cell
pretreat
glycopyrronium
formoterol
budesonid
alon
nm
fig
mrna
asl
protein
level
uninfect
hte
cell
pretreat
formoterol
gfb
lower
vehicletr
cell
fig
c
pretreat
glycopyrronium
formoterol
gfb
decreas
fluoresc
intens
acid
endosom
compar
vehicletr
cell
fig
infect
pretreat
formoterol
gfb
reduc
baselin
secret
compar
vehicletr
cell
fig
f
infect
increas
level
h
level
h
infect
data
h
shown
pretreat
glycopyrronium
formoterol
budesonid
gfb
reduc
infectioninduc
increas
secret
compar
vehicl
fig
f
concentr
gfbtreat
cell
lower
cell
treat
glycopyrronium
formoterol
budesonid
alon
fig
f
cape
mgml
reduc
signific
differ
compar
valu
hte
cell
infect
treat
vehicl
glycopyrronium
formoterol
budesonid
indic
p
p
p
p
p
respect
bed
signific
differ
compar
valu
uninfect
hte
cell
treat
vehicl
glycopyrronium
formoterol
budesonid
indic
p
p
p
p
yy
p
p
respect
eei
signific
differ
compar
valu
uninfect
vehicletr
hte
cell
indic
p
p
signific
differ
compar
valu
hte
cell
infect
treat
vehicl
glycopyrronium
formoterol
budesonid
indic
p
p
p
p
p
respect
infectioninduc
increas
secret
fig
f
ici
mm
revers
inhibitori
effect
formoterol
viral
titer
mrna
protein
level
acid
endosom
product
fig
mrna
level
ifnb
ifnl
ifng
hte
cell
increas
infect
pretreat
glycopyrronium
formoterol
budesonid
gfb
decreas
level
fig
contrast
protein
concentr
ifnb
ifnl
ifng
asl
basolater
supernat
detect
limit
demonstr
pretreat
primari
hne
hte
cell
cultur
glycopyrronium
formoterol
combin
three
drug
glycopyrronium
formoterol
budesonid
gfb
reduc
replic
cytokin
concentr
asl
select
b
adrenerg
receptor
antagonist
ici
revers
inhibitori
effect
formoterol
formoterol
gfb
reduc
express
receptor
inhibitor
dipyridyl
reduc
viral
titer
find
suggest
drug
inhibit
replic
partli
via
regul
receptor
express
reduct
titer
express
hne
cell
pretreat
camp
similar
level
secret
supernat
cell
treat
formoterol
inhibitori
effect
formoterol
express
consist
result
previou
report
danielsen
et
al
found
express
intestin
mucosa
decreas
forskolin
activ
adenyl
cyclas
activ
formoterol
therefor
formoterol
may
decreas
replic
partli
modul
receptor
express
via
camp
product
addit
pretreat
glycopyrronium
formoterol
gfb
reduc
number
fluoresc
intens
acid
endosom
rna
enter
cytoplasm
therefor
drug
may
also
inhibit
replic
inhibit
function
acid
endosom
endosom
ph
regul
vacuolar
h
atpas
ion
transport
across
na
h
exchang
camp
increas
endosom
ph
inhibit
na
h
exchang
demonstr
formoterol
increas
camp
level
hne
cell
decreas
number
acid
endosom
previous
report
hte
cell
therefor
formoterol
may
inhibit
function
na
h
exchang
via
product
camp
cell
furthermor
acetylcholin
activ
h
k
atpas
gastric
cell
bafilomycin
inhibitor
h
atpas
inhibit
acetylcholineinduc
increas
cytoplasm
ph
therefor
glycopyrronium
may
inhibit
activ
h
k
atpas
andor
h
atpas
airway
epitheli
cell
glycopyrronium
concentr
lung
estim
ngml
nm
accord
deliveri
rate
lung
furthermor
found
formoterol
gfb
decreas
viral
titer
concentr
nm
similar
level
plasma
formoterol
report
previous
literatur
therefor
glycopyrronium
formoterol
may
reduc
replic
safe
clinic
dose
relat
airway
inflamm
copd
bronchial
asthma
exacerb
induc
viral
infect
decreas
product
cell
pretreat
glycopyrronium
formoterol
budesonid
well
increas
inhibitori
effect
gfb
observ
present
studi
may
associ
inhibitori
effect
drug
copd
bronchial
asthma
exacerb
present
studi
signific
mrna
level
ifnb
ifnl
ifng
detect
cell
product
reduc
treatment
drug
although
concentr
ifnb
ifnl
ifng
asl
basolater
supernat
undetect
find
consist
previou
studi
demonstr
rhinovir
infect
induc
innat
immun
stimul
interferon
system
human
airway
epitheli
cell
treatment
fluticason
reduc
ifn
product
reduc
product
ifnb
ifnl
ifng
could
associ
decreas
replic
suppress
tolllik
receptor
acetylcholin
induc
nfkb
activ
associ
cytokin
product
formoterol
budesonid
shown
inhibit
nfkb
activ
addit
nfkb
inhibitor
cape
decreas
product
infect
therefor
reduc
nfkb
activ
could
associ
inhibit
cytokin
product
drug
use
present
studi
budesonid
decreas
titer
express
howev
budesonid
inhibit
rhinovir
replic
reduc
express
receptor
although
subject
nasal
tissu
obtain
treat
variou
drug
includ
corticosteroid
pretreat
budesonid
reduc
replic
hte
cell
patient
treat
corticosteroid
sorrel
et
al
demonstr
corticosteroid
reduc
express
fibroblast
therefor
differ
effect
budesonid
receptor
express
may
lead
differ
effect
replic
rhinovirus
hne
hte
cell
use
sever
studi
respiratori
viral
infect
use
hne
hte
cell
previous
use
cell
infect
studi
howev
bronchi
alveoli
main
site
pathogenesi
copd
bronchial
asthma
exacerb
bronchial
alveolar
epitheli
cell
use
reveal
effect
viral
infect
exacerb
effect
drug
therefor
studi
use
bronchial
alveolar
epitheli
cell
need
confirm
replic
effect
drug
studi
first
demonstr
glycopyrronium
formoterol
combin
glycopyrronium
